Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00104910
Other study ID # GOG-9918
Secondary ID NCI-2009-00621CD
Status Completed
Phase Phase 1
First received March 3, 2005
Last updated December 29, 2014
Start date January 2005

Study information

Verified date December 2014
Source Gynecologic Oncology Group
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase I trial is studying the side effects and best dose of cetuximab when given together with cisplatin and radiation therapy in treating patients with stage IB, stage II, stage III, or stage IVA cervical cancer. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving cetuximab together with cisplatin and radiation therapy may kill more tumor cells.


Description:

PRIMARY OBJECTIVES:

I. Determine the maximum tolerated dose or safe biologically effective dose of cetuximab when administered in combination with cisplatin, external beam radiotherapy, and brachytherapy in patients with stage IB-IVA cervical cancer.

II. Determine the feasibility of this regimen, in terms of chronic and acute toxic effects, in these patients.

SECONDARY OBJECTIVES:

I. Determine the distribution of progression-free survival and overall survival of patients treated with this regimen at 1 year after study entry.

II. Determine the site of recurrence (locoregional vs distant) in patients treated with this regimen up to 1 year after study entry.

III. Correlate response or progression-free survival with epidermal growth factor receptor expression in tumor samples from patients treated with this regimen at 1 year after study entry.

IV. Correlate response or progression-free survival with grade of cetuximab-induced rash in patients treated with this regimen at 1 year after study entry.

OUTLINE: This is a multicenter, dose-escalation study of cetuximab. Patients are stratified according to nodal status (positive para-aortic and/or pelvic lymph nodes vs negative para-aortic and pelvic lymph nodes).

Patients receive cetuximab IV over 1-2 hours and cisplatin IV on days 1, 8, 15, 22, 29, and 36 (weeks 1-6). Patients also undergo external beam radiotherapy to the para-aortic and pelvic lymph nodes OR whole pelvis once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33 (weeks 1-5). Patients then receive either 1 or 2 applications of low-dose rate brachytherapy in weeks 6-8 OR 5 applications of high-dose rate (HDR)* brachytherapy once weekly in weeks 4-8. Treatment continues in the absence of disease progression or unacceptable toxicity.

NOTE: *No external beam radiotherapy is administered on the day of HDR brachytherapy. If the majority of external beam radiotherapy has been administered, HDR brachytherapy may be administered in 2 applications per week (separated by at least 72 hours) in order to complete all treatment within 8 weeks.

Cohorts of 3-6 patients per stratum receive escalating doses of cetuximab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

After completion of study treatment, patients are followed every 3 months for 1 year.


Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date
Est. primary completion date January 2013
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed cervical cancer

- Clinical stage IB-IVA disease

- Any cell type allowed

- Positive or negative pelvic and/or para-aortic lymph nodes by radiography

- Unstained sections from primary tumor available

- Performance status - GOG 0-1

- Absolute neutrophil count = 1,500/mm^3

- Platelet count = 100,000/mm^3

- Bilirubin = 1.5 times upper limit of normal (ULN)

- SGOT = 2.5 times ULN

- Alkaline phosphatase = 2.5 times ULN

- Creatinine normal

- Creatinine clearance > 50 mL/min

- Patients with ureteral obstruction must undergo stent or nephrostomy tube placement prior to study entry

- No renal abnormality (e.g., pelvic kidney or horseshoe kidney) that would require modification of radiation fields

- No significant cardiac disease within the past 6 months, including any of the following:

- Uncontrolled hypertension

- Unstable angina

- Congestive heart failure

- Uncontrolled arrhythmia

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No sensory or motor neuropathy > grade 1

- No septicemia

- No severe infection

- No circumstance that would preclude study participation or follow-up

- No other invasive malignancy within the past 5 years except nonmelanoma skin cancer

- No uncontrolled seizure disorder

- No active neurologic disease

- No history of active collagen vascular disease

- No prior chimerized or murine monoclonal antibody therapy

- No prior cytotoxic chemotherapy for cervical cancer

- No prior pelvic or abdominal radiotherapy for cervical cancer

- No concurrent intensity modulated radiotherapy

- No prior renal transplantation

- More than 30 days since prior major surgery (excluding diagnostic biopsy)

- No other prior therapy for cervical cancer

- No prior cancer treatment that would preclude study therapy

- No other concurrent investigational agents

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Radiation:
Internal Radiation Therapy

3-Dimensional Conformal Radiation Therapy

Biological:
Cetuximab
Given IV
Drug:
Cisplatin
Given IV

Locations

Country Name City State
United States Georgia Regents University Medical Center Augusta Georgia
United States Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland
United States Cooper Hospital University Medical Center Camden New Jersey
United States University of Chicago Comprehensive Cancer Center Chicago Illinois
United States Cleveland Clinic Foundation Cleveland Ohio
United States MetroHealth Medical Center Cleveland Ohio
United States Riverside Methodist Hospital Columbus Ohio
United States Parkland Memorial Hospital Dallas Texas
United States University of Texas Southwestern Medical Center Dallas Texas
United States M D Anderson Cancer Center Houston Texas
United States Indiana University/Melvin and Bren Simon Cancer Center Indianapolis Indiana
United States University of Iowa Hospitals and Clinics Iowa City Iowa
United States Lake University Ireland Cancer Center Mentor Ohio
United States University of Oklahoma Health Sciences Center Oklahoma City Oklahoma
United States Women and Infants Hospital Providence Rhode Island

Sponsors (2)

Lead Sponsor Collaborator
Gynecologic Oncology Group National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose (MTD) or biologically effective dose (BED) of Cetuximab in combination with cisplatin and extended field radiation or whole pelvis radiation, graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) Evaluation of the regimens will be conducted separately by the type of radiation received (extended field radiation or whole pelvis radiation). 6 weeks Yes
Primary Incidence of toxicities at the MTD, assessed by CTCAE v3.0 Up to 1 year Yes
Secondary Progression-free survival From study entry until disease progression, death or date of last contact, up to 1 year No
Secondary Site of recurrence, loco-regional vs distant, assessed by clinical and radiological evaluation From study entry until disease progression, death or date of last contact, up to 1 year No
Secondary Frequency of chronic toxicities, assessed by CTCAE v3.0 From study entry until disease progression, death or date of last contact, up to 1 year Yes
See also
  Status Clinical Trial Phase
Completed NCT02562729 - Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer Phase 2
Completed NCT00054444 - Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer Phase 1
Completed NCT00416455 - Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Phase 1/Phase 2
Recruiting NCT05210348 - Clinical Evaluation of Detection of High Risk HPV in Urine
Active, not recruiting NCT02140021 - Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer N/A
Completed NCT00068549 - Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer Phase 1
Completed NCT01711515 - Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer Phase 1
Terminated NCT00924066 - Ixabepilone to Treat Cervical Cancer Phase 2
Completed NCT00559377 - FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer Phase 2
Completed NCT00309959 - ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2
Active, not recruiting NCT05613283 - Primary Cervical Cancer Screening by Self-sampling HPV Test
Recruiting NCT03742869 - HPV Integration and Tumorigenesis of Uterine Cervical Adenocarcinoma
Withdrawn NCT03834571 - Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women Phase 2
Completed NCT01266460 - Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2
Completed NCT00064077 - Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Phase 3
Active, not recruiting NCT02257528 - Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Phase 2
Active, not recruiting NCT02466971 - Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers Phase 3
Completed NCT02164461 - Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer Phase 1
Completed NCT01281852 - Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Phase 1
Active, not recruiting NCT04622670 - Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Patients With Stage IB2-IIIB Cervical Cancer N/A